Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Brian D. Green · GLYCOBIA, INC. · 2019 · $300,000 — PROJECT SUMMARY/ABSTRACT Almost half of all men and women in the United States will be diagnosed with cancer during their lifetimes, resulting in more than 500,000 deaths and an economic burden exceeding $200 billion annually. Cancer immunotherapies, such as vaccines and antibodies, are emerging str…
Eva Maria Carmona Porquera · MAYO CLINIC ROCHESTER · 2019 · $79,500 — PROJECT SUMMARY/ABSTRACT B-cells are increasingly linked to a number of fibrotic lung diseases (FLD) and it is well recognized that they form aggregates, known as inducible bronchus associated lymphoid tissue (iBALTs) in the lung of many of these patients. Our studies demonstrate that when activated…
Derek B. Sant'Angelo · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · 2019 · $477,000 — Summary There are at least 49 members of the BTB-ZF gene family, which includes PLZF, BCL6, ThPOK, LRF and others. Only a few have been studied in the context of immune system development or function. Expression of the known BTB-ZF genes correlates with specific functions of the cells – in many ways…
Scott G Hansen · OREGON HEALTH & SCIENCE UNIVERSITY · 2019 · $819,581 — Project Summary With 36 million people currently living with HIV worldwide, developing a prophylactic HIV vaccine that protects against sexual transmission remains a top global health priority. A pre-clinical HIV vaccine approach based on strain 68-1 of rhesus cytomegalovirus expressing SIV antigens…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2019 · $800,558 — PROJECT SUMMARY Studying Natural SIV Reservoirs and Human Zoonotic Risk, we discovered in the last funding period that certain strains of SIV infecting Old World monkeys and African apes share unexpected antigenic cross- reactivity with HIV-1 in the functionally important V1V2 region of the envelope…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $350,000 — NHP immunized with 10 and 100g of mRNA-1273 encoding the SARS CoV2 had robust neutralizing antibodiy titers following two immunizations. mRNA-1273 induced Th1-biased CD4 T cell responses and low or undetectable Th2 or CD8 T responses. Following an infectious challenge with SARS CoV2 by the intrana…
Christopher Parks · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $14,125 — PROJECT SUMMARY The overall goal of this project is to develop and compare three new HIV envelope (Env) trimer delivery vaccines that are designed to mimic the natural presentation of the transmembrane glycoprotein complex (the spike) that occurs during HIV infection. Our vaccine design approach …
JOHN H. SAMPSON · DUKE UNIVERSITY · 2020 · $691,384 — PROJECT SUMMARY – Project 1 We recently reported in Nature that patients with glioblastoma (GBM) randomized to receive a vaccine against Cytomegalovirus (CMV) major integument protein pp65 using a tetanus/diphtheria (Td) vaccine site preconditioning regimen had a statistically significant increase i…
CATHERINE MARY O'CONNELL · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $165,241 — In a subset of Chlamydia trachomatis-infected women, the infection escapes immune control and ascends to the upper reproductive tract. There is a fundamental gap in understanding how pathways activated by chlamydial infection lead to immune pathology and reproductive morbidity in women. Its continue…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $277,719 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
Thomas Denny · DUKE UNIVERSITY · 2020 · $1,949,407 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2020 · $221,729 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $3,194,965 — Administrative Core The IPCAVD Administrative Core will serve to coordinate all scientific and administrative activities of the Duke IPCAVD, ensuring that the Projects and Cores function well together. A primary activity of the Core will be monitoring IPCAVD progress relative to milestones and measu…
Sallie R. Permar · DUKE UNIVERSITY · 2020 · $354,930 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
CHRISTOPHER P. HILL · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2020 · $311,488 — ABSTRACT The success of antiretroviral therapy (ART) has transformed the HIV/AIDS pandemic into a life-long chronic disease, yet major challenges remain as a growing population of ~35 million patients living with HIV continues to face significant health challenges. These include side-effects and tox…
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2020 · $4,735 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
GARY FUJII · MOLECULAR EXPRESS, INC. · 2020 · $299,993 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
Laimonis A. LAIMINS · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $355,500 — PROJECT SUMMARY Human papillomaviruses (HPV) are the causative agents of cervical, anal and many oral cancers. While prophylactic vaccines to prevent HPV infections have been developed, there is no effective therapeutic treatment for existing HPV lesions. It is therefore of critical importance to un…
Julie Magarian Blander · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $419,267 — PROPOSAL SUMMARY Live attenuated vaccines have proven to be the most efficient human vaccines for many serious infectious diseases. When compared to their dead counterparts, live vaccines induce superior immune protection and lasting memory. But despite the efficacy of live vaccines, concerns over t…
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2020 · $340,875 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…